Susan B. Panozzo

Assistant Director of Clinical Research Operations

UAMS

7 h-index 30 pubs 455 cited

Research Areas

Biomedical Subjects

OverviewAI-generated summary

Susan B. Panozzo's research focuses on the treatment and outcomes of multiple myeloma, a hematologic malignancy. Her work has investigated various therapeutic strategies, including the use of ex vivo-expanded natural killer cells for relapsed patients, and the efficacy of combining bortezomib and thalidomide with fractionated melphalan transplants for patients with adverse cytogenetics. Panozzo has also studied the role of maintenance therapy, such as VRD, and explored the potential of pomalidomide in high-risk relapsed and refractory multiple myeloma patients. Her publications have examined treatment goals, such as suppression of focal lesions on positron emission tomography-computed tomography, and have also addressed cardiac complications associated with treatments like carfilzomib. Panozzo's recent work includes long-term follow-up studies of patients treated on various Total Therapy protocols, providing insights into the sustained impact of these regimens. She collaborates with researchers at the University of Arkansas for Medical Sciences, including Clyde Bailey, Michele Cottler-Fox, Shmuel Yaccoby, and Erming Tian.

Metrics

h-index: 7
Publications: 30
Citations: 455

Positions

Assistant Director of Clinical Research Operations publications 2009–2025

University of Arkansas for Medical Sciences Institution web page

Selected Publications

Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025)

JAMA Oncology 7 citations DOI OpenAlex
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024)

Blood Advances 6 citations DOI OpenAlex
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up (2023)

Blood Advances 11 citations DOI OpenAlex
Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma (2023)

Blood DOI OpenAlex
Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups (2019)

Blood 2 citations DOI OpenAlex
Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma (2018)

Haematologica 76 citations DOI OpenAlex
Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants (2016)

Clinical Cancer Research 14 citations DOI OpenAlex
A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant (2015)

Blood 2 citations DOI OpenAlex
Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib (2015)

Blood Cancer Journal 113 citations DOI OpenAlex
Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM) (2014)

Blood 2 citations DOI OpenAlex
Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma (2014)

Leukemia 10 citations DOI OpenAlex
Total Therapy (TT) Studies For Gene Expression Profiling (GEP)-Defined High-Risk Multiple Myeloma (2013)

Blood DOI OpenAlex
Impact Of Elotuzumab Therapy On Circulating and Ex Vivo Activated/Expanded Autologous Natural Killer (Auto-ENK) Cell Activity (2013)

Blood DOI OpenAlex
Final Results Of Phase II Study Of Pomalidomide (Pom) In GEP-Defined High Risk Relapsed and Refractory Multiple Myeloma (RRMM) (2013)

Blood 6 citations DOI OpenAlex
Phase II Study of Pomalidomide (Pom) in Genomically Defined High Risk Relapsed and Refractory Multiple Myeloma (RRMM) (2012)

Blood 5 citations DOI OpenAlex